Amgen (AMGN) Short-term Investments (2009 - 2023)

Amgen has reported Short-term Investments for 15 years, with the latest figure at $1.0 million in Q1 2023.

• On a quarterly basis, Short-term Investments fell 93.75% year-over-year to $1.0 million in Q1 2023; TTM through Mar 2023 was $1.0 million, a 93.75% decrease from a year earlier, with the FY2022 full-year figure at $1.7 billion, up 3391.67% from the prior year.
• Short-term Investments was $1.0 million for Q1 2023 at Amgen, down from $1.7 billion in the prior quarter.
• The five-year high for Short-term Investments was $18.9 billion in Q1 2019, with the low at $1.0 million in Q1 2023.
• Average Short-term Investments over 5 years is $4.1 billion, with a median of $2.0 billion recorded in 2022.
• The largest YoY upside for Short-term Investments was 3391.67% in 2022 against a maximum downside of 99.64% in 2022.
• Over 5 years, Short-term Investments stood at $2.9 billion in 2019, then jumped by 52.44% to $4.4 billion in 2020, then tumbled by 98.9% to $48.0 million in 2021, then soared by 3391.67% to $1.7 billion in 2022, then slumped by 99.94% to $1.0 million in 2023.
• The last three Short-term Investments figures came in at $1.0 million (Q1 2023), $1.7 billion (Q4 2022), and $2.0 billion (Q3 2022), per Business Quant data.